Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Google Secures Pentagon AI Deal for Classified Projects 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
HAMPTON, N.J., Feb. 04, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 2:40 p.m. EST in New York City.
The live webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected]
